Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03985449 · ClinicalTrials.gov registry record · NA
Implementation of Uterine Fibroid Option Grid Patient Decision Aids Across Five Organizational Settings
A NA study of Uterine Fibroid, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 748
- Enrollment target
- 1
- Study location
NCT03985449: Completed NA study of Uterine Fibroid, sponsored by Dartmouth-Hitchcock Medical Center.
NCT03985449 is a NA study of Uterine Fibroid that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 748 participants, above the 172-participant average among 5 other Uterine Fibroid trials with a reported enrollment target (335% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03985449, a NA study of Uterine Fibroid, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 748 participants
- Enrollment target
- 1
- Study location
Study Summary
UPFRONT is a study that aims to use two implementation frameworks - the Consolidated Framework for Implementation Research and the Normalization Process Theory - to guide the implementation of a uterine fibroid patient decision aid, known as Option Grid, at five diverse gynecology settings across the United States. Option Grid provides evidence-based information on the various treatment options to help women across socioeconomic strata with symptomatic uterine fibroids make a preference-sensitive decision.
Conditions Studied
Interventions
- OTHER Uterine Fibroid Option Grid encounter patient decision aid (text only)
- OTHER Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures)
- OTHER Uterine Fibroid Option Grid encounter patient decision aid (online)
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 748 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2023-01-15 |
| Phase | NA |
What the finished NCT03985449 record still lists
NCT03985449 is an interventional study that assigns participants to a tested intervention. The registered 748 participants enrollment target is mid-sized for trials with a published cap, above the 172-participant average among 5 other Uterine Fibroid trials with a reported enrollment target (335% higher).
The record links to 1 condition, with Uterine Fibroid appearing as the primary indexed condition, and to 3 interventions - of which Uterine Fibroid Option Grid encounter patient decision aid (text only) is the first listed.
NCT03985449 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT03985449 about?
NCT03985449 is a clinical study titled "Implementation of Uterine Fibroid Option Grid Patient Decision Aids Across Five Organizational Settings". UPFRONT is a study that aims to use two implementation frameworks - the Consolidated Framework for Implementation Research and the Normalization Process Theory - to guide the implementation of a uterine fibroid patient decision aid, known as Option Grid, at five diverse gynecology settings across th...
What is the current status of trial NCT03985449?
This trial is currently completed. It is a NA study. The enrollment target is 748 participants. The study started on 2019-08-01. Estimated completion is 2023-01-15.
What conditions does trial NCT03985449 study?
This clinical trial studies the following conditions: Uterine Fibroid.
What interventions are being tested in trial NCT03985449?
The interventions under investigation include: Uterine Fibroid Option Grid encounter patient decision aid (text only) (OTHER), Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures) (OTHER), Uterine Fibroid Option Grid encounter patient decision aid (online) (OTHER).
Who is sponsoring clinical trial NCT03985449?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03985449 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Fibroid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Life Study: Lifestyle Intervention in Fibroid Elimination
ACTIVE NOT RECRUITING · NA
-
Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids
RECRUITING
-
Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE
RECRUITING · Phase 2
-
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
COMPLETED · Phase 3
-
An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI